1,2,3,9b-Tetrahydro-5H-imidazo2,1-aisoindol-5-ones as a new class of respiratory syncytial virus (RSV) fusion inhibitors. Part 2: Identification of BTA9881 as a preclinical candidate
Journal Articles Refereed